Ruíz-Patiño, Alejandro
Rojas, Leonardo
Zuluaga, Jairo
Arrieta, Oscar
Corrales, Luis
Martín, Claudio
Franco, Sandra
Raez, Luis
Rolfo, Christian
Sánchez, Natalia
Cardona, Andrés Felipe http://orcid.org/0000-0003-3525-4126
Funding for this research was provided by:
Universidad El Bosque
Article History
Received: 23 September 2023
Accepted: 20 February 2024
First Online: 6 April 2024
Declarations
:
: Jairo Zuluaga received honoraria as an advisor and participated in speakers' bureau of Astra Zeneca, Bristol Myers Squibb, and Pfizer. Leonardo Rojas received honoraria as an advisor and participated in speakers' bureau from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Astra Zeneca, and Eli Lilly. Additionally, he was linked and received honoraria as a researcher. Oscar Arrieta reports personal fees from Pfizer, grants and individual fees from Astra Zeneca, grants, and individual fees from Boehringer- Ingelheim, personal fees from Lilly, individual fees from Merck, personal fees from Bristol Myers Squibb, grants, and personal fees from Roche, outside the submitted work. Andrés F. Cardona discloses financial research support from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, and The Foundation for Clinical and Applied Cancer Research – FICMAC. Additionally, he was linked and received honoraria as an advisor, participated in the speakers' bureau, and gave expert testimony to Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, and Foundation for Clinical and Applied Cancer Research – FICMAC.
: Not applicable.
: Not applicable.